Within the LFB Group, which is a leader in the field of therapeutic proteins in France, LFB USA enables the production of life-saving medicines within the Group’s key areas of expertise and focus – immunology, intensive care and hemostasis. By providing development, manufacturing, quality control, quality assurance, clinical and regulatory capabilities and services, LFB USA is cultivating life-changing therapeutic proteins for patients with serious and often rare diseases.
The company is leveraging our rPRO Technology™ to develop much-needed innovative therapeutic proteins for patients with serious and rare diseases - high potential medicinal products from LFB S.A.’s pipeline. The most advanced of these programs is a proprietary recombinant form of human Factor VIIa which was approved by the FDA for treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies). The Phase III studies in pediatric and surgical patients are now complete and will be filed soon to the FDA for review/approval for these follow-on indications.
In an effort to continually explore additional medicines made possible by this unique approach to therapeutic protein development, LFB USA is also a services provider to other organizations who share our vision.
Interested in learning more? Contact LFB USA Business Development by email.
For more information on Factor VIIa, please visit the Sevenfact® website.